1026MO A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors

R-H. Xu, Shujie Wang, Wenjun Wei et al.|Annals of Oncology|2023

Cited by 1